NextPharma Set to Acquire Two Lonza Sites Specialized in Lipid Oral Dosage Forms

. Agreement initiates process for future acquisition of Lonza sites in Ploermel (FR) and Edinburgh (UK) allowing NextPharma to broaden technology offering into lipid finished dosage forms Centers of excellence employing a total of 390 staff offer expertise in Lipid Oral Dosage Forms including softgels and liquid-filled hard capsules for the pharma and nutrition markets Read more about NextPharma Set to Acquire Two Lonza Sites Specialized in Lipid Oral Dosage Forms[…]

ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy

ViGeneron GmbH, a gene therapy company, today announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”), for delivering a novel therapeutic protein to address an undisclosed target in a highly prevalent ophthalmic disease. ViGeneron’s vgAAVs enable the efficient transduction of target cells via intravitreal Read more about ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy[…]

„Supreme Harmony“ for OVD Needs

VSY Biotechnology Introduces Protectalon DUO Kit, demonstrating commitment to Ophthalmic Surgery! Eye Care Professionals meet their OVD needs at different stages of cataract surgery with a single kit. It is available now for safe, fast and smooth surgery! SPECIFICATIONS: Dual Pack containing one unit cohesive and one unit dispersive OVDs High Filling Volume (1.1 ml Cohesive Read more about „Supreme Harmony“ for OVD Needs[…]

ViGeneron and WuXi Advanced Therapies enter Strategic Manufacturing Partnership for Next-Generation Ophthalmic Gene Therapy

ViGeneron, a gene therapy company, and WuXi Advanced Therapies Inc. (WuXi ATU), a leading Contract, Testing, Development and Manufacturing Organization (CTDMO), today announced a strategic partnership to accelerate production for the clinical development of VG901, a next-generation ophthalmic gene therapy program. ViGeneron’s innovative gene therapy pipeline addresses ophthalmic diseases with high unmet medical needs. Its Read more about ViGeneron and WuXi Advanced Therapies enter Strategic Manufacturing Partnership for Next-Generation Ophthalmic Gene Therapy[…]

Live at the CPhI China: Gerresheimer presents innovative special products for the packaging and administration of medicines

One of the most important events for pharmaceutical packaging and drug delivery in Asia is CPhI China. It will take place – LIVE – from 16 to 18 December 2020 in the well-known venue SNIEC Shanghai, at booth N5P21. It is the first pharmaceutical trade fair to go live again during the global pandemic situation, Read more about Live at the CPhI China: Gerresheimer presents innovative special products for the packaging and administration of medicines[…]

CPhI – festival of pharma: Dose eye drops even more precisely with DropControl

With DropControl, Gerresheimer has developed a new type of dropper insert for modern drugs with low viscosity for ophthalmology, which prevents the drug from flowing in uncontrollably during use. “Lots of people need eye drops regularly. It is therefore important that these vials function reliably and simply to the last drop. With DropControl, it is Read more about CPhI – festival of pharma: Dose eye drops even more precisely with DropControl[…]

Munu’s Eyes: FLIR Perimeter Solution Secures the World’s Last Rhinos

South Africa conservationist Brett Barlow needed a robust security solution to protect Munu, a blind, South Western Black Rhinoceros whose species is critically endangered. Barlow deployed an all FLIR solution, comprising thermal cameras, visible cameras and an NVR, for around-the-clock monitoring, early detection and real-time response. FLIR technology has played an instrumental role to protect Read more about Munu’s Eyes: FLIR Perimeter Solution Secures the World’s Last Rhinos[…]